GlassScriptPhysician profile
Richard L Gilbert
NPI 1336230747
$5,270.37
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $1,062 · 2021: $1,242 · 2022: $868 · 2023: $958 · 2024: $74.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $718.58 | 2019-2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $712.57 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Novo Nordisk INC | $603.88 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $306.49 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $188.71 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $185.71 | 2019-2021 | |
| Abbott Laboratories | $185.53 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $185.04 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $174.99 | 2022 | |
| Amarin Pharma, INC. | $156.16 | 2019-2021 | |
| Eisai INC. | $141.65 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.94 | 2019-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $131.57 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.75 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $108.08 | 2020-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.